CClinicalTrials.gg
CompletedNCT03535636PSG-PTSDUpdated Feb 24, 2023

Sleep Impairments in Refugees Diagnosed With PTSD

An observational study in PTSD and Sleep Disorder, sponsored by Mental Health Services in the Capital Region, Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-24.

Sponsored by Mental Health Services in the Capital Region, Denmark · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to examine sleep architecture in refugees with PTSD. Polysomnography (PSG) will be carried out to study the occurrence of sleep disorders in patients and healthy controls.

Read the detailed description

There is little knowledge on treatment of sleep disturbances in trauma-affected refugees and this study will be the first to record the biophysiological changes that occur during sleep in refugees with PTSD. The study is a proof-of-concept study and this will contribute with new and potentially crucial knowledge of sleep disturbances in these patients.

The project is designed as a cross-sectional study with 20 refugees with PTSD referred to the specialised outpatient clinic, Competence Centre for Transcultural Psychiatry (CTP), and 20 healthy control subjects.

All patients referred to CTP will be invited to an initial consultation with a doctor. During this consultation a diagnostic assessment will be performed and the clinical history will be obtained. Patients who give informed consent will be invited to participate in the project and have sleep measurements performed by PSG. Furthermore self-administered questionnaires and semi-structured interviews will be used to collect information on mental health, sleep quality, sleep length and nightmares.

Each patient will be equipped with PSG equipment to do measurements at home for one night (12 hours). Healthy control subjects will fill out the same CTP standard ratings and have the same diagnostic assessment and PSG measurement.

The hypothesis is that the sleep architecture in refugees with PTSD differ from healthy controls. It is suggested that refugees with PTSD have increased dream activity as well as increased incidence of sleep disorders such as rapid eye movement (REM) sleep without atonia (RSWA), REM sleep behaviour disorder (RBD), sleep apnea and periodic limb movement disorder (PLM).

The study is performed in collaboration with Danish Centre for Sleep Medicine in Denmark.

02

Conditions studied

  • PTSD
  • Sleep Disorder

Browse trials for

Keywords

  • Polysomnography
  • Refugees
03

In context

Sleep Wake Disorders

788 studies on the registry are indexed under Sleep Wake Disorders; 186 are open to participants now.

This study's enrollment of 40 is below the median of 114 across 215 observational studies indexed under Sleep Wake Disorders.

Browse Sleep Wake Disorders studies →

Lead sponsor

Mental Health Services in the Capital Region, Denmark is the lead sponsor of 51 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population includes patients referred to the specialised outpatient clinic 'Competence Centre for Transcultural Psychiatry' (CTP) in Denmark. The clinic treats adult refugees, migrants or people with family reunification who has a traumatic background eg. imprisonment with torture, organised violence, long term political pursuit or war experiences. The patients at the clinic has PTSD, depression and/or anxiety.

Healthy control subjects are matched on age, sex and BMI.

Inclusion criteria

  • Adults (18 years old or above)
  • Refugee or family reunification refugees
  • PTSD according to the ICD-10 criteria's
  • Signed informed concent

Exclusion criteria

Exclusion Criteria:

  • Severe psychotic disorder (defined as patients with ICD-10 diagnoses F2x and F30.1-F30.9)
  • Harmful use of alcohol (ICD-10 diagnosis F1x.1)
  • Serious or progressive somatic illnesses that the lead investigator finds interfering for the study
  • Medical treatment with antipsychotics, benzodiazepine, opioids, CNS stimulants or regular use of anti histamine
  • BMI >35
  • Pregnancy
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
40 participants (actual)
Target follow-up
30 Days
Patient registry
Yes

Groups and cohorts

  • Refugees with PTSD

    Adults over the age of 18. Refugees or family members of refugees that has been reunited. PTSD (ICD-10 criteria) and written consent. No drug or alcohol abuse and no medication that can affect sleep rhythms, such as antipsychotic drugs, benzodiazepine, opioids, antihistamine or CNS stimulating drugs. A BMI under 35 and no pregnancy.

    Other: Polysomnography

  • Healthy controls

    Matched on age, sex and BMI and signed written consent. No mental illness, drug or alcohol abuse and medication. No pregnancy.

    Other: Polysomnography

Interventions

  • OtherPolysomnography

    Sleep architecture will be assessed by polysomnography

06

What researchers measure

Primary outcomes

  1. Assessing the incidence of sleep disorders in refugees with PTSD

    Sleep architecture will be assessed by polysomnography. The recording of brain activity during sleep will reveal the incidence of sleep disorders such as sleep apnea, REM sleep without atonia and REM sleep behaviour disorder

    Time frame: 12 hours

Secondary outcomes

  1. Global Assessment of Functioning (GAF S + F)

    A numeric scale used to subjectively rate the social, occupational, and psychological functioning of an individual

    Time frame: 10 minutes

  2. Harvard Trauma Questionnaire (HTQ)

    Assessing PTSD symptoms

    Time frame: 10 minutes

  3. Hopkins Symptom Check List-25 (HSCL-25)

    Assessing anxiety and depression symptoms

    Time frame: 10 minutes

  4. World Health Organization Well-Being Index (WHO-5)

    Assessing subjective psychological well-being

    Time frame: 10 minutes

  5. Sheehan Disability Scale (SDS)

    The SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10), Social life (0-10), Family life/home responsibilities (0-10). Scores of ≥5 on any of the 3 scales; high scores are associated with significant functional impairment.

    Time frame: 10 minutes

  6. Schedule for Clinical Assessment in Neuropsychiatry (SCAN)

    Diagnosing and measuring mental illness that may occur in adult life.

    Time frame: 1 hours

  7. Clinician Administered PTSD Scale (CAPS-5)

    Assessing PTSD symptoms, including their frequency and severity. The gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview and requires the identification of a single index trauma to serve as the basis of symptom inquiry. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms. Similarly, CAPS-5 symptom cluster severity scores are calculated by summing the individual item severity scores for symptoms corresponding to a given DSM-5 cluster: Criterion B (items 1-5); Criterion C (items 6-7); Criterion D (items 8-14); and, Criterion E (items 15-20). A symptom cluster score may also be calculated for dissociation by summing items 19 and 20. A patient needs to have: at least one Criterion B and C symptom and at least two Criterion D and E symptoms. Criterion F is met (disturbance has lasted one month) and Criterion G is met (disturbance causes either clinically significant distress or functional impairment).

    Time frame: 1 hour

  8. Hamilton depression scale (HAM-D17)

    Assessing a patient's severity of depression before, during, and after treatment. The HAM-D probes 17 parameters. Some items are scored on a 5-point scale, ranging from 0=not present to 4=severe; others are scored on a 3-point scale, ranging from 0=not present to 2=severe. Total score 0-52 (0 unimpaired, 52 highly impaired). The sum of all 17 items indicate the severity of depression; 0-12 = normal, 13-17 = mild depression, 18-24 = moderate depression, 24-52 severe depression.

    Time frame: 15 minutes

  9. Hamilton anxiety scale (HAM-A14)

    Assessing the severity of a patient's anxiety. The HAM-A probes 14 items. Each item is scored on a 5-point scale, ranging from 0=not present to 4=severe. Total score 0-56 (0 unimpaired, 56 highly impaired). The sum of all 14 items indicate the severity of anxiety; 14-17 = mild anxiety, 18-24 = moderate anxiety, 25-30 severe anxiety.

    Time frame: 15 minutes

  10. The Pittsburgh Sleep Quality Index (PSQI)

    Assessing sleep quality and sleep disorders

    Time frame: 10 minutes

  11. Disturbing dreams and Nightmare Severity Index (DDNSI)

    Assessing nightmares

    Time frame: 10 minutes

  12. REM Sleep Behavior Disorder Screening Questionnaire (RBDSC)

    Assessing REM Sleep Behavior Disorders

    Time frame: 10 minutes

  13. Life Events Checklist for DSM-5 (LEC-5) - extended version

    Screening of potential traumatic events

    Time frame: 10 minutes

07

Study locations

1 site
  • Competence Center for Transcultural Psychiatry
    Ballerup, 2750, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03535636
Lead sponsor
Mental Health Services in the Capital Region, Denmark
Collaborators
Danish Center for Sleep Medicine
Responsible party
Mia Beicher Ansbjerg (Pregraduate Researcher, Mental Health Services in the Capital Region, Denmark) — Principal investigator
First posted
May 24, 2018
Start date
Apr 20, 2018
Primary completion
Feb 7, 2023
Completion
Feb 7, 2023
Last update
Feb 24, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion